Redox imbalance in lung cancer of patients with underlying chronic respiratory conditions

Molecular Medicine

Volumn 22, Issue , 2016, Pages 85-98

  Mateu Jiménez, Mercè ^a,b   Sánchez Font, Albert ^a,b   Rodríguez Fuster, Alberto ^c   Aguiló, Rafael ^c   Pijuan, Lara ^d   Fermoselle, Clara ^a,b   Gea, Joaquim ^a,b   Curull, Víctor ^a,b   Barreiro, Esther ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Surgery Department   (Spain)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; SUPEROXIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SUSCEPTIBILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NITRATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN CONTENT; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 84987638673     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00199     Document Type: Article

References (52)

1. Alvarez Martinez CJ, et al. (2014) Guideline on management of solitary pulmonary nodule. Arch. Bronconeumol. 50:285–93.
2. Leiro-Fernandez V, et al. (2014) Changes in clinical presentation and staging of lung cancer over two decades. Arch. Bronconeumol. 50:417–21.
3. Rodriguez, M. et al. (2015) Poorer survival in stage IB lung cancer patients after pneumonectomy. Arch. Bronconeumol. 51:223–6.
4. Rodriguez M, et al. (2015) Morbidity and mortality in octogenarians with lung cancer undergoing pneumonectomy. Arch. Bronconeumol. 51:219–22.
5. Sanchez-Salcedo P, et al. (2015) Lung cancer screening: fourteen year experience of the Pamplona Early Detection Program (P-IELCAP). Arch. Bronconeumol. 51:169–76.
6. Sanchez de Cos EJ, et al. (2013) The Spanish Society of Pulmonology and Thoracic Surgery Lung Cancer Cooperative Group-II registry. A descriptive study. Arch. Bronconeumol. 49:462–7.
7. Sanchez de Cos J, et al. (2011) SEPAR guidelines for lung cancer staging. Arch. Bronconeumol. 47:454–65.
8. Gupta A, et al. (2010) Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology. 15:349–56.
9. Masri FA, et al. (2005) Abnormalities in nitric oxide and its derivatives in lung cancer. Am. J. Respir. Crit. Care Med. 172:597–605.
10. Pignatelli B, et al. (2001) Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res. 61:778–84.
11. Rahman I, Morrison D, Donaldson K, MacNee W. (1996) Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med. 154:1055–60.
12. Rahman I, et al. (2002) 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166:490–5.
13. Herbst RS, Heymach JV, Lippman, SM. (2008) Lung cancer. N. Engl. J. Med. 359:1367–80.
14. Grimm EA, Sikora AG, Ekmekcioglu S. (2013) Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin. Cancer Res. 19:5557–63.
15. Esme H, et al. (2008) High levels of oxidative stress in patients with advanced lung cancer. Respirology. 13:112–6.
16. Friguet B, Stadtman ER, Szweda LI. (1994) Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of crosslinked protein that inhibits the multicatalytic protease. J. Biol. Chem. 269:21639–43.
17. Requena JR, et al. (1996) Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol. Dial. Transplant. 11 Suppl 5:48–53.
18. Stadtman ER, Levine RL. (2003) Free radicalmediated oxidation of free amino acids and amino acid residues in proteins. Amino.Acids. 25:207–18.
19. Cadet J, et al. (2012) Biologically relevant oxidants and terminology, classification and nomenclature of oxidatively generated damage to nucleobases and 2-deoxyribose in nucleic acids. Free Radic. Res. 46:367–81.
20. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA. (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G—T and A—C substitutions. J. Biol. Chem. 267:166–72.
21. Evans MD, Cooke MS. (2004) Factors contributing to the outcome of oxidative damage to nucleic acids. Bioessays. 26:533–42.
22. Evans MD, Saparbaev M, Cooke MS. (2010) DNA repair and the origins of urinary oxidized 2′-deoxyribonucleosides. Mutagenesis. 25:433–42.
23. Barreiro E, et al. (2013) Oxidative stress and inflammation in the normal airways and blood of patients with lung cancer and COPD. Free Radic. Biol. Med. 65:859–71.
24. Glasauer A, Sena LA, Diebold LP, Mazar AP, Chandel NS. (2014) Targeting SOD1 reduces experimental non-small-cell lung cancer. J. Clin. Invest. 124:117–28.
25. Miar A, et al. (2015) Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/ GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer. Free Radic. Biol. Med. 85:45–55.
26. Carpagnano GE, et al. (2007) IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol. Res. 16:375–81.
27. Miravitlles M, Calle M, Soler-Cataluna JJ. (2012) Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch. Bronconeumol. 48:86–98.
28. Miravitlles M, et al. (2014) Spanish guideline for COPD (GesEPOC). Update 2014. Arch. Bronconeumol 50 Suppl 1:1–16.
29. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. (2013) Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143:e278S–313S.
30. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. (2013) Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143:e400S–19S.
31. Kozower BD, Larner JM, Detterbeck FC, Jones DR. (2013) Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143:e369S–99S.
32. Chacon-Cabrera A, et al. (2014) Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J. Cell. Physiol. 229:1660–72.
33. Fermoselle C, et al. (2012) Does oxidative stress modulate limb muscle atrophy in severe COPD patients? Eur. Respir. J. 40:851–62.
34. Marin-Corral J, et al. (2009) Oxidised proteins and superoxide anion production in the diaphragm of severe COPD patients. Eur. Respir. J. 33:1309–19.
35. Rodriguez DA, et al. (2012) Muscle and blood redox status after exercise training in severe COPD patients. Free Radic. Biol. Med. 52:88–94.
36. Li Y, et al. (1998) Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J. Biol. Chem. 273:2015–23.
37. de Torres JP, et al. (2007) Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 132:1932–8.
38. Lopez Varela MV, et al. (2013) Comorbidities and health status in individuals with and without COPD in five Latin American cities: the PLATINO study. Arch. Bronconeumol. 49:468–74.
39. Skillrud DM, Offord KP, Miller RD. (1986) Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann. Intern. Med. 105:503–7.
40. Young JF, et al. (2010) Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative NMR-based metabonomics and proteomics. J. Int. Soc. Sports Nutr. 7:9.
41. Alam S, Li Z, Janciauskiene S, Mahadeva R. (2011) Oxidation of Z α1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am. J. Respir. Cell Mol. Biol. 45:261–9.
42. Li Z, et al. (2009) Oxidized {alpha}1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema. Am. J. Physiol. Lung Cell Mol. Physiol. 297:L388–400.
43. Connor KM, et al. (2007) Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res. 67:10260–7.
44. Hempel N, Carrico PM, Melendez JA. (2011) Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis. Anticancer Agents Med. Chem. 11:191–201.
45. Ishii K, et al. (1996) Prevention of mammary tumorigenesis in acatalasemic mice by vitamin E supplementation. Jpn. J. Cancer Res. 87:680–4.
46. Barreiro E, et al. (2008) Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 63:100–7.
47. Litwack G, Ketterer B, Arias IM. (1971) Ligandin: a hepatic protein which binds steroids, bilirubin, carcinogens and a number of exogenous organic anions. Nature. 234:466–7.
48. Gallegos-Arreola MP, et al. (2003) GSTT1 gene deletion is associated with lung cancer in Mexican patients. Dis. Markers. 19:259–61.
49. Zhao Y, et al. (2015) Glutathione S-transferase θ1 polymorphism contributes to lung cancer susceptibility: a meta-analysis of 26 case-control studies. Oncol. Lett. 9:1947–53.
50. Gorrini C, Harris IS, Mak TW. (2013) Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12:931–47.
51. Trachootham D, Alexandre J, Huang P. (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8:579–91.
52. Parente Lamelas I, et al. (2011) Lung cancer in women: a comparison with men and an analysis of cases diagnosed in Ourense (Spain) 1999–2006. Arch. Bronconeumol. 47:61–5.